Hydroxychloroquine Market By Application (Rheumatoid Arthritis, Lupus Erythematosus, Malaria, Coronavirus (COVID-19), Others); By Product Type (200 mg, 300 mg, 400 mg, Others); By Distribution Channel (Online, Offline (Retail Pharmacies, Hospitals/Clinics, Others)); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries , Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Global hydroxychloroquine market was estimated to be US$ 41.3 Mn in 2018 and is expected to reach US$ 100.4 Mn by 2027 growing at a CAGR of 10.4% over the forecast period. Human immune system protects us against foreign harmful organisms including viruses, bacterial among others. Some diseases affect immune system in such a way that it leads to immune deficiency or immune system by mistake attacking healthy body cells. The disorder in which immune system is unable to detect foreign objects and acts body’s healthy cells are known as autoimmune disorders. Some of the notable disorders which alter the functioning of immune system include rheumatoid arthritis, lupus erythematosus, type 1 diabetes and malaria among others. These disorders are treated with a combination of therapies and medications. One of the known treatment methods for these diseases include the administration of hydroxychloroquine for the affected patients.
Hydroxychloroquine is observed to aid human immune system and help in limiting the spread of the diseases. Owing to these characteristics, hydroxychloroquine has become a centre of attention for healthcare professionals as a probable cure against coronavirus (COVID-19) disease, which is seen to be targeting the immune system of a person. There are numerous healthcare organizations along with educational and research institutions that are undertaking clinical trials for understanding the effectiveness of the drug against coronavirus (COVID-19) which subsequently is increasing the size of global hydroxychloroquine market.
By Application
Drugs made using hydroxychloroquine are prescribed to patients when they are facing disorders which is affecting their autoimmune systems. The notable diseases and disorders in this category include rheumatoid arthritis, lupus erythematosus, and malaria amongst others. In 2020, the coronavirus (COVID-19) has affected numerous patients across the world. The virus has been observed to affect the immune system of the patient. In order to combat this disease, doctors in various countries have been prescribing hydroxychloroquine to patients. The disease is observed to be limited in a preventive and a curative manner through the use of hydroxychloroquine. Hence, the use of the drug for limiting the spread of the coronavirus (COVID-19) thus increasing the size of global hydroxychloroquine market over the forecast period.
By Product Type
The optimal strength of a drug that is prescribed for a patient is necessary for a speedy recovery. Hydroxychloroquine is available to patients in various strengths namely, 200 mg, 300 mg, and 400 mg amongst others. The drug is notably available in the form of tablets and can be procured through a branded formulation or through the generic drug formulation. In traditional autoimmune disorders such as rheumatoid arthritis and malaria, the dosages prescribed were based on the type of patient. Children were observed to be prescribed with 200 mg dosages while adults were observed to be prescribed with 400 mg dosages of hydroxychloroquine in most cases of autoimmune disorders. The strengths of the drug that have been prescribed for acute autoimmune conditions are observed to go above the regular dosages owing to support the patient’s immune system and lead towards an improved protection against the disease. However, the side effects of the drug such as headaches and dizziness amongst others have alerted doctors to provide optimal strengths of the drug to their respective patients, in the current outbreak of coronavirus (COVID-19). Thus all these factors thus increasing the size of global hydroxychloroquine market over the forecast period.
By Distribution Channel
Hydroxychloroquine is available to patients in various channels. The most notable channel for distribution of hydroxychloroquine is observed to be through offline outlets. Pharmacies, hospitals and government health centres have been providing the general population with hydroxychloroquine for various autoimmune disorders. The online medium is observed to be utilized more in the developed countries across the world thus increasing the size of global hydroxychloroquine market over the forecast period.
By Region
Due to prevalence of malaria, hydroxychloroquine which is anti-malarial drug is manufactured more in Asia Pacific region. Countries including India, and China among others have significant production capacity in production of hydroxychloroquine. The wide range of the diseases for which hydroxychloroquine is used as a drug along with the rising cases of autoimmune diseases more notably, lupus erythematosus and malaria in Asia Pacific is expected to aid the growing demand for hydroxychloroquine across the region in recent years. The sudden rise in coronavirus (COVID-19) cases in North America have led to a rise in demand and increase in market size of global hydroxychloroquine market.
Hydroxychloroquine Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of hydroxychloroquine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the hydroxychloroquine market are Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories, Inc, Ipca Laboratories Ltd., Laurus Labs Limited, Mylan N.V., NorthStar Rx LLC, Novartis AG, Prasco Laboratories, Sanofi, Teva Pharmaceutical Industries Ltd., and Zydus Cadila, among others.
Hydroxychloroquine Market:
By Application
- Rheumatoid Arthritis
- Lupus Erythematosus
- Malaria
- Coronavirus (COVID-19)
- Others
By Product Type
- 200 mg
- 300 mg
- 400 mg
- Others
By Distribution Channel
Online
Offline
- Retail Pharmacies
- Hospitals/Clinics
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Hydroxychloroquine Market
6. Market Synopsis:
Hydroxychloroquine Market
7. Hydroxychloroquine Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Hydroxychloroquine Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Hydroxychloroquine Market
7.6. Porter’s
Five Force Analysis
8. Global Hydroxychloroquine Market Analysis and Forecasts, 2019
– 2027
8.1. Overview
8.1.1. Global
Hydroxychloroquine Market Revenue (US$ Mn)
8.2. Global
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
8.2.1. Rheumatoid
Arthritis
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Lupus
Erythematosus
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. Malaria
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Coronavirus
(COVID-19)
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2013 – 2018
8.2.4.3. Market
Forecast, 2019 – 2027
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2013 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2013 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2013 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2013 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2013 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.2.5. Others
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2013 – 2018
8.2.5.3. Market
Forecast, 2019 – 2027
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2013 – 2018
8.2.5.5.1.2. Market
Forecast, 2019 – 2027
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2013 – 2018
8.2.5.5.2.2. Market
Forecast, 2019 – 2027
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2013 – 2018
8.2.5.5.3.2. Market
Forecast, 2019 – 2027
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2013 – 2018
8.2.5.5.4.2. Market
Forecast, 2019 – 2027
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2013 – 2018
8.2.5.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Application
9. Global Hydroxychloroquine Market Analysis and Forecasts, 2019
– 2027
9.1. Overview
9.2. Global
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
9.2.1. 200 mg
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. 300 mg
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. 400 mg
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Product Type
10. Global Hydroxychloroquine Market Analysis and Forecasts, 2019
– 2027
10.1. Overview
10.2. Global
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
10.2.1. Online
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Offline
(Definition, Market Estimation and Penetration, 2013 – 2018, Market Estimation
(2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Retail Pharmacies, Hospitals/Clinics,
Others)
10.2.2.1. Retail
Pharmacies
10.2.2.2. Hospitals/Clinics
10.2.2.3. Others
10.3. Key
Segment for Channeling Investments
10.3.1. By
Distribution Channel
11. North America Hydroxychloroquine Market Analysis and
Forecasts, 2019 - 2027
11.1. Overview
11.1.1. North
America Hydroxychloroquine Market Revenue (US$ Mn)
11.2. North
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
11.2.1. Rheumatoid
Arthritis
11.2.2. Lupus
Erythematosus
11.2.3. Malaria
11.2.4. Coronavirus
(COVID-19)
11.2.5. Others
11.3. North
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
11.3.1. 200 mg
11.3.2. 300 mg
11.3.3. 400 mg
11.3.4. Others
11.4. North
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.4.1. Online
11.4.2. Offline
11.4.2.1. Retail
Pharmacies
11.4.2.2. Hospitals/Clinics
11.4.2.3. Others
11.5. North
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.1.1. Rheumatoid
Arthritis
11.5.1.1.2. Lupus
Erythematosus
11.5.1.1.3. Malaria
11.5.1.1.4. Coronavirus
(COVID-19)
11.5.1.1.5. Others
11.5.1.2. U.S
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
11.5.1.2.1. 200
mg
11.5.1.2.2. 300
mg
11.5.1.2.3. 400
mg
11.5.1.2.4. Others
11.5.1.3. U.S
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.5.1.3.1. Online
11.5.1.3.2. Offline
11.5.1.3.2.1. Retail
Pharmacies
11.5.1.3.2.2. Hospitals/Clinics
11.5.1.3.2.3. Others
11.5.2. Canada
11.5.2.1. Canada
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.1.1. Rheumatoid
Arthritis
11.5.2.1.2. Lupus
Erythematosus
11.5.2.1.3. Malaria
11.5.2.1.4. Coronavirus
(COVID-19)
11.5.2.1.5. Others
11.5.2.2. Canada
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
11.5.2.2.1. 200
mg
11.5.2.2.2. 300
mg
11.5.2.2.3. 400
mg
11.5.2.2.4. Others
11.5.2.3. Canada
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.5.2.3.1. Online
11.5.2.3.2. Offline
11.5.2.3.2.1. Retail
Pharmacies
11.5.2.3.2.2. Hospitals/Clinics
11.5.2.3.2.3. Others
11.5.3. Mexico
11.5.3.1. Mexico
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.1.1. Rheumatoid
Arthritis
11.5.3.1.2. Lupus
Erythematosus
11.5.3.1.3. Malaria
11.5.3.1.4. Coronavirus
(COVID-19)
11.5.3.1.5. Others
11.5.3.2. Mexico
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
11.5.3.2.1. 200
mg
11.5.3.2.2. 300
mg
11.5.3.2.3. 400
mg
11.5.3.2.4. Others
11.5.3.3. Mexico
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.5.3.3.1. Online
11.5.3.3.2. Offline
11.5.3.3.2.1. Retail
Pharmacies
11.5.3.3.2.2. Hospitals/Clinics
11.5.3.3.2.3. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.4.1.1. Rheumatoid
Arthritis
11.5.4.1.2. Lupus
Erythematosus
11.5.4.1.3. Malaria
11.5.4.1.4. Coronavirus
(COVID-19)
11.5.4.1.5. Others
11.5.4.2. Rest
of North America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Product Type
11.5.4.2.1. 200
mg
11.5.4.2.2. 300
mg
11.5.4.2.3. 400
mg
11.5.4.2.4. Others
11.5.4.3. Rest
of North America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.5.4.3.1. Online
11.5.4.3.2. Offline
11.5.4.3.2.1. Retail
Pharmacies
11.5.4.3.2.2. Hospitals/Clinics
11.5.4.3.2.3. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Application
11.6.3. By
Product Type
11.6.4. By
Distribution Channel
12. Europe Hydroxychloroquine Market Analysis and Forecasts, 2019
- 2027
12.1. Overview
12.1.1. Europe
Hydroxychloroquine Market Revenue (US$ Mn)
12.2. Europe
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
12.2.1. Rheumatoid
Arthritis
12.2.2. Lupus
Erythematosus
12.2.3. Malaria
12.2.4. Coronavirus
(COVID-19)
12.2.5. Others
12.3. Europe
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
12.3.1. 200 mg
12.3.2. 300 mg
12.3.3. 400 mg
12.3.4. Others
12.4. Europe
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.4.1. Online
12.4.2. Offline
12.4.2.1. Retail
Pharmacies
12.4.2.2. Hospitals/Clinics
12.4.2.3. Others
12.5. Europe
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.1.1. Rheumatoid
Arthritis
12.5.1.1.2. Lupus
Erythematosus
12.5.1.1.3. Malaria
12.5.1.1.4. Coronavirus
(COVID-19)
12.5.1.1.5. Others
12.5.1.2. France
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.1.2.1. 200
mg
12.5.1.2.2. 300
mg
12.5.1.2.3. 400
mg
12.5.1.2.4. Others
12.5.1.3. France
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.1.3.1. Online
12.5.1.3.2. Offline
12.5.1.3.2.1. Retail
Pharmacies
12.5.1.3.2.2. Hospitals/Clinics
12.5.1.3.2.3. Others
12.5.2. The UK
12.5.2.1. The
UK Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.1.1. Rheumatoid
Arthritis
12.5.2.1.2. Lupus
Erythematosus
12.5.2.1.3. Malaria
12.5.2.1.4. Coronavirus
(COVID-19)
12.5.2.1.5. Others
12.5.2.2. The
UK Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.2.2.1. 200
mg
12.5.2.2.2. 300
mg
12.5.2.2.3. 400
mg
12.5.2.2.4. Others
12.5.2.3. The
UK Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.2.3.1. Online
12.5.2.3.2. Offline
12.5.2.3.2.1. Retail
Pharmacies
12.5.2.3.2.2. Hospitals/Clinics
12.5.2.3.2.3. Others
12.5.3. Spain
12.5.3.1. Spain
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.1.1. Rheumatoid
Arthritis
12.5.3.1.2. Lupus
Erythematosus
12.5.3.1.3. Malaria
12.5.3.1.4. Coronavirus
(COVID-19)
12.5.3.1.5. Others
12.5.3.2. Spain
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.3.2.1. 200
mg
12.5.3.2.2. 300
mg
12.5.3.2.3. 400
mg
12.5.3.2.4. Others
12.5.3.3. Spain
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.3.3.1. Online
12.5.3.3.2. Offline
12.5.3.3.2.1. Retail
Pharmacies
12.5.3.3.2.2. Hospitals/Clinics
12.5.3.3.2.3. Others
12.5.4. Germany
12.5.4.1. Germany
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.1.1. Rheumatoid
Arthritis
12.5.4.1.2. Lupus
Erythematosus
12.5.4.1.3. Malaria
12.5.4.1.4. Coronavirus
(COVID-19)
12.5.4.1.5. Others
12.5.4.2. Germany
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.4.2.1. 200
mg
12.5.4.2.2. 300
mg
12.5.4.2.3. 400
mg
12.5.4.2.4. Others
12.5.4.3. Germany
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.4.3.1. Online
12.5.4.3.2. Offline
12.5.4.3.2.1. Retail
Pharmacies
12.5.4.3.2.2. Hospitals/Clinics
12.5.4.3.2.3. Others
12.5.5. Italy
12.5.5.1. Italy
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.1.1. Rheumatoid
Arthritis
12.5.5.1.2. Lupus
Erythematosus
12.5.5.1.3. Malaria
12.5.5.1.4. Coronavirus
(COVID-19)
12.5.5.1.5. Others
12.5.5.2. Italy
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.5.2.1. 200
mg
12.5.5.2.2. 300
mg
12.5.5.2.3. 400
mg
12.5.5.2.4. Others
12.5.5.3. Italy
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.5.3.1. Online
12.5.5.3.2. Offline
12.5.5.3.2.1. Retail
Pharmacies
12.5.5.3.2.2. Hospitals/Clinics
12.5.5.3.2.3. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.6.1.1. Rheumatoid
Arthritis
12.5.6.1.2. Lupus
Erythematosus
12.5.6.1.3. Malaria
12.5.6.1.4. Coronavirus
(COVID-19)
12.5.6.1.5. Others
12.5.6.2. Nordic
Countries Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
12.5.6.2.1. 200
mg
12.5.6.2.2. 300
mg
12.5.6.2.3. 400
mg
12.5.6.2.4. Others
12.5.6.3. Nordic
Countries Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.5.6.3.1. Online
12.5.6.3.2. Offline
12.5.6.3.2.1. Retail
Pharmacies
12.5.6.3.2.2. Hospitals/Clinics
12.5.6.3.2.3. Others
12.5.6.4. Nordic
Countries Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.1.1. Rheumatoid
Arthritis
12.5.7.1.2. Lupus
Erythematosus
12.5.7.1.3. Malaria
12.5.7.1.4. Coronavirus
(COVID-19)
12.5.7.1.5. Others
12.5.7.2. Benelux
Union Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
12.5.7.2.1. 200
mg
12.5.7.2.2. 300
mg
12.5.7.2.3. 400
mg
12.5.7.2.4. Others
12.5.7.3. Benelux
Union Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.7.3.1. Online
12.5.7.3.2. Offline
12.5.7.3.2.1. Retail
Pharmacies
12.5.7.3.2.2. Hospitals/Clinics
12.5.7.3.2.3. Others
12.5.7.4. Benelux
Union Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.8.1.1. Rheumatoid
Arthritis
12.5.8.1.2. Lupus
Erythematosus
12.5.8.1.3. Malaria
12.5.8.1.4. Coronavirus
(COVID-19)
12.5.8.1.5. Others
12.5.8.2. Rest
of Europe Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
12.5.8.2.1. 200
mg
12.5.8.2.2. 300
mg
12.5.8.2.3. 400
mg
12.5.8.2.4. Others
12.5.8.3. Rest
of Europe Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.5.8.3.1. Online
12.5.8.3.2. Offline
12.5.8.3.2.1. Retail
Pharmacies
12.5.8.3.2.2. Hospitals/Clinics
12.5.8.3.2.3. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Application
12.6.3. By
Product Type
12.6.4. By
Distribution Channel
13. Asia Pacific Hydroxychloroquine Market Analysis and
Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Asia
Pacific Hydroxychloroquine Market Revenue (US$ Mn)
13.2. Asia
Pacific Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
13.2.1. Rheumatoid
Arthritis
13.2.2. Lupus
Erythematosus
13.2.3. Malaria
13.2.4. Coronavirus
(COVID-19)
13.2.5. Others
13.3. Asia
Pacific Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
13.3.1. 200 mg
13.3.2. 300 mg
13.3.3. 400 mg
13.3.4. Others
13.4. Asia
Pacific Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.4.1. Online
13.4.2. Offline
13.4.2.1. Retail
Pharmacies
13.4.2.2. Hospitals/Clinics
13.4.2.3. Others
13.5. Asia
Pacific Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.1.1. Rheumatoid
Arthritis
13.5.1.1.2. Lupus
Erythematosus
13.5.1.1.3. Malaria
13.5.1.1.4. Coronavirus
(COVID-19)
13.5.1.1.5. Others
13.5.1.2. China
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.1.2.1. 200
mg
13.5.1.2.2. 300
mg
13.5.1.2.3. 400
mg
13.5.1.2.4. Others
13.5.1.3. China
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.1.3.1. Online
13.5.1.3.2. Offline
13.5.1.3.2.1. Retail
Pharmacies
13.5.1.3.2.2. Hospitals/Clinics
13.5.1.3.2.3. Others
13.5.2. Japan
13.5.2.1. Japan
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.1.1. Rheumatoid
Arthritis
13.5.2.1.2. Lupus
Erythematosus
13.5.2.1.3. Malaria
13.5.2.1.4. Coronavirus
(COVID-19)
13.5.2.1.5. Others
13.5.2.2. Japan
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.2.2.1. 200
mg
13.5.2.2.2. 300
mg
13.5.2.2.3. 400
mg
13.5.2.2.4. Others
13.5.2.3. Japan
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.2.3.1. Online
13.5.2.3.2. Offline
13.5.2.3.2.1. Retail
Pharmacies
13.5.2.3.2.2. Hospitals/Clinics
13.5.2.3.2.3. Others
13.5.3. India
13.5.3.1. India
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.1.1. Rheumatoid
Arthritis
13.5.3.1.2. Lupus
Erythematosus
13.5.3.1.3. Malaria
13.5.3.1.4. Coronavirus
(COVID-19)
13.5.3.1.5. Others
13.5.3.2. India
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.3.2.1. 200
mg
13.5.3.2.2. 300
mg
13.5.3.2.3. 400
mg
13.5.3.2.4. Others
13.5.3.3. India
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.3.3.1. Online
13.5.3.3.2. Offline
13.5.3.3.2.1. Retail
Pharmacies
13.5.3.3.2.2. Hospitals/Clinics
13.5.3.3.2.3. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.4.1.1. Rheumatoid
Arthritis
13.5.4.1.2. Lupus
Erythematosus
13.5.4.1.3. Malaria
13.5.4.1.4. Coronavirus
(COVID-19)
13.5.4.1.5. Others
13.5.4.2. New
Zealand Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
13.5.4.2.1. 200
mg
13.5.4.2.2. 300
mg
13.5.4.2.3. 400
mg
13.5.4.2.4. Others
13.5.4.3. New
Zealand Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.4.3.1. Online
13.5.4.3.2. Offline
13.5.4.3.2.1. Retail
Pharmacies
13.5.4.3.2.2. Hospitals/Clinics
13.5.4.3.2.3. Others
13.5.5. Australia
13.5.5.1. Australia
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.1.1. Rheumatoid
Arthritis
13.5.5.1.2. Lupus
Erythematosus
13.5.5.1.3. Malaria
13.5.5.1.4. Coronavirus
(COVID-19)
13.5.5.1.5. Others
13.5.5.2. Australia
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.5.2.1. 200
mg
13.5.5.2.2. 300
mg
13.5.5.2.3. 400
mg
13.5.5.2.4. Others
13.5.5.3. Australia
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.5.3.1. Online
13.5.5.3.2. Offline
13.5.5.3.2.1. Retail
Pharmacies
13.5.5.3.2.2. Hospitals/Clinics
13.5.5.3.2.3. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.6.1.1. Rheumatoid
Arthritis
13.5.6.1.2. Lupus
Erythematosus
13.5.6.1.3. Malaria
13.5.6.1.4. Coronavirus
(COVID-19)
13.5.6.1.5. Others
13.5.6.2. South
Korea Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.6.2.1. 200
mg
13.5.6.2.2. 300
mg
13.5.6.2.3. 400
mg
13.5.6.2.4. Others
13.5.6.3. South
Korea Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.6.3.1. Online
13.5.6.3.2. Offline
13.5.6.3.2.1. Retail
Pharmacies
13.5.6.3.2.2. Hospitals/Clinics
13.5.6.3.2.3. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.1.1. Rheumatoid
Arthritis
13.5.7.1.2. Lupus
Erythematosus
13.5.7.1.3. Malaria
13.5.7.1.4. Coronavirus
(COVID-19)
13.5.7.1.5. Others
13.5.7.2. Southeast
Asia Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
13.5.7.2.1. 200
mg
13.5.7.2.2. 300
mg
13.5.7.2.3. 400
mg
13.5.7.2.4. Others
13.5.7.3. Southeast
Asia Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.7.3.1. Online
13.5.7.3.2. Offline
13.5.7.3.2.1. Retail
Pharmacies
13.5.7.3.2.2. Hospitals/Clinics
13.5.7.3.2.3. Others
13.5.7.4. Southeast
Asia Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.8.1.1. Rheumatoid
Arthritis
13.5.8.1.2. Lupus
Erythematosus
13.5.8.1.3. Malaria
13.5.8.1.4. Coronavirus
(COVID-19)
13.5.8.1.5. Others
13.5.8.2. Rest
of Asia Pacific Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Product Type
13.5.8.2.1. 200
mg
13.5.8.2.2. 300
mg
13.5.8.2.3. 400
mg
13.5.8.2.4. Others
13.5.8.3. Rest
of Asia Pacific Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.8.3.1. Online
13.5.8.3.2. Offline
13.5.8.3.2.1. Retail
Pharmacies
13.5.8.3.2.2. Hospitals/Clinics
13.5.8.3.2.3. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Application
13.6.3. By
Product Type
13.6.4. By
Distribution Channel
14. Middle East and Africa Hydroxychloroquine Market Analysis and
Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Middle
East and Africa Hydroxychloroquine Market Revenue (US$ Mn)
14.2. Middle
East and Africa Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
14.2.1. Rheumatoid
Arthritis
14.2.2. Lupus
Erythematosus
14.2.3. Malaria
14.2.4. Coronavirus
(COVID-19)
14.2.5. Others
14.3. Middle
East and Africa Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Product Type
14.3.1. 200 mg
14.3.2. 300 mg
14.3.3. 400 mg
14.3.4. Others
14.4. Middle
East and Africa Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.4.1. Online
14.4.2. Offline
14.4.2.1. Retail
Pharmacies
14.4.2.2. Hospitals/Clinics
14.4.2.3. Others
14.5. Middle
East and Africa Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1.1.1. Rheumatoid
Arthritis
14.5.1.1.2. Lupus
Erythematosus
14.5.1.1.3. Malaria
14.5.1.1.4. Coronavirus
(COVID-19)
14.5.1.1.5. Others
14.5.1.2. Saudi
Arabia Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
14.5.1.2.1. 200
mg
14.5.1.2.2. 300
mg
14.5.1.2.3. 400
mg
14.5.1.2.4. Others
14.5.1.3. Saudi
Arabia Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.1.3.1. Online
14.5.1.3.2. Offline
14.5.1.3.2.1. Retail
Pharmacies
14.5.1.3.2.2. Hospitals/Clinics
14.5.1.3.2.3. Others
14.5.2. UAE
14.5.2.1. UAE
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.1.1. Rheumatoid
Arthritis
14.5.2.1.2. Lupus
Erythematosus
14.5.2.1.3. Malaria
14.5.2.1.4. Coronavirus
(COVID-19)
14.5.2.1.5. Others
14.5.2.2. UAE
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.2.2.1. 200
mg
14.5.2.2.2. 300
mg
14.5.2.2.3. 400
mg
14.5.2.2.4. Others
14.5.2.3. UAE
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.2.3.1. Online
14.5.2.3.2. Offline
14.5.2.3.2.1. Retail
Pharmacies
14.5.2.3.2.2. Hospitals/Clinics
14.5.2.3.2.3. Others
14.5.3. Egypt
14.5.3.1. Egypt
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.1.1. Rheumatoid
Arthritis
14.5.3.1.2. Lupus
Erythematosus
14.5.3.1.3. Malaria
14.5.3.1.4. Coronavirus
(COVID-19)
14.5.3.1.5. Others
14.5.3.2. Egypt
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.3.2.1. 200
mg
14.5.3.2.2. 300
mg
14.5.3.2.3. 400
mg
14.5.3.2.4. Others
14.5.3.3. Egypt
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.3.3.1. Online
14.5.3.3.2. Offline
14.5.3.3.2.1. Retail
Pharmacies
14.5.3.3.2.2. Hospitals/Clinics
14.5.3.3.2.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.1.1. Rheumatoid
Arthritis
14.5.4.1.2. Lupus
Erythematosus
14.5.4.1.3. Malaria
14.5.4.1.4. Coronavirus
(COVID-19)
14.5.4.1.5. Others
14.5.4.2. Kuwait
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
14.5.4.2.1. 200
mg
14.5.4.2.2. 300
mg
14.5.4.2.3. 400
mg
14.5.4.2.4. Others
14.5.4.3. Kuwait
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.4.3.1. Online
14.5.4.3.2. Offline
14.5.4.3.2.1. Retail
Pharmacies
14.5.4.3.2.2. Hospitals/Clinics
14.5.4.3.2.3. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
14.5.5.1.1. Rheumatoid
Arthritis
14.5.5.1.2. Lupus
Erythematosus
14.5.5.1.3. Malaria
14.5.5.1.4. Coronavirus
(COVID-19)
14.5.5.1.5. Others
14.5.5.2. South
Africa Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
14.5.5.2.1. 200
mg
14.5.5.2.2. 300
mg
14.5.5.2.3. 400
mg
14.5.5.2.4. Others
14.5.5.3. South
Africa Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.5.3.1. Online
14.5.5.3.2. Offline
14.5.5.3.2.1. Retail
Pharmacies
14.5.5.3.2.2. Hospitals/Clinics
14.5.5.3.2.3. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Hydroxychloroquine Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.6.1.1. Rheumatoid
Arthritis
14.5.6.1.2. Lupus
Erythematosus
14.5.6.1.3. Malaria
14.5.6.1.4. Coronavirus
(COVID-19)
14.5.6.1.5. Others
14.5.6.2. Rest
of Middle East & Africa Hydroxychloroquine Market Revenue (US$ Mn) and
Forecasts, By Product Type
14.5.6.2.1. 200
mg
14.5.6.2.2. 300
mg
14.5.6.2.3. 400
mg
14.5.6.2.4. Others
14.5.6.3. Rest
of Middle East & Africa Hydroxychloroquine Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.6.3.1. Online
14.5.6.3.2. Offline
14.5.6.3.2.1. Retail
Pharmacies
14.5.6.3.2.2. Hospitals/Clinics
14.5.6.3.2.3. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Application
14.6.3. By
Product Type
14.6.4. By Distribution
Channel
15. Latin America Hydroxychloroquine Market Analysis and
Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Latin
America Hydroxychloroquine Market Revenue (US$ Mn)
15.2. Latin
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
15.2.1. Rheumatoid
Arthritis
15.2.2. Lupus
Erythematosus
15.2.3. Malaria
15.2.4. Coronavirus
(COVID-19)
15.2.5. Others
15.3. Latin
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product
Type
15.3.1. 200 mg
15.3.2. 300 mg
15.3.3. 400 mg
15.3.4. Others
15.4. Latin
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.4.1. Online
15.4.2. Offline
15.4.2.1. Retail
Pharmacies
15.4.2.2. Hospitals/Clinics
15.4.2.3. Others
15.5. Latin
America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.1.1. Rheumatoid
Arthritis
15.5.1.1.2. Lupus
Erythematosus
15.5.1.1.3. Malaria
15.5.1.1.4. Coronavirus
(COVID-19)
15.5.1.1.5. Others
15.5.1.2. Brazil
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
15.5.1.2.1. 200
mg
15.5.1.2.2. 300
mg
15.5.1.2.3. 400
mg
15.5.1.2.4. Others
15.5.1.3. Brazil
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.5.1.3.1. Online
15.5.1.3.2. Offline
15.5.1.3.2.1. Retail
Pharmacies
15.5.1.3.2.2. Hospitals/Clinics
15.5.1.3.2.3. Others
15.5.2. Argentina
15.5.2.1. Argentina
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.1.1. Rheumatoid
Arthritis
15.5.2.1.2. Lupus
Erythematosus
15.5.2.1.3. Malaria
15.5.2.1.4. Coronavirus
(COVID-19)
15.5.2.1.5. Others
15.5.2.2. Argentina
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Product Type
15.5.2.2.1. 200
mg
15.5.2.2.2. 300
mg
15.5.2.2.3. 400
mg
15.5.2.2.4. Others
15.5.2.3. Argentina
Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.5.2.3.1. Online
15.5.2.3.2. Offline
15.5.2.3.2.1. Retail
Pharmacies
15.5.2.3.2.2. Hospitals/Clinics
15.5.2.3.2.3. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.3.1.1. Rheumatoid
Arthritis
15.5.3.1.2. Lupus
Erythematosus
15.5.3.1.3. Malaria
15.5.3.1.4. Coronavirus
(COVID-19)
15.5.3.1.5. Others
15.5.3.2. Rest
of Latin America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Product Type
15.5.3.2.1. 200
mg
15.5.3.2.2. 300
mg
15.5.3.2.3. 400
mg
15.5.3.2.4. Others
15.5.3.3. Rest
of Latin America Hydroxychloroquine Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.5.3.3.1. Online
15.5.3.3.2. Offline
15.5.3.3.2.1. Retail
Pharmacies
15.5.3.3.2.2. Hospitals/Clinics
15.5.3.3.2.3. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Application
15.6.3. By
Product Type
15.6.4. By
Distribution Channel
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2018
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Amneal
Pharmaceuticals LLC.
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Dr.
Reddy’s Laboratories, Inc.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Ipca
Laboratories Ltd.
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Laurus
Labs Limited
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Mylan
N.V.
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. NorthStar
Rx LLC
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Novartis
AG
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Prasco
Laboratories
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Sanofi
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Teva
Pharmaceutical Industries Ltd.
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Zydus
Cadila
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Other
Market Participants
18. Key Findings
Note: This ToC is tentative and can
be changed according to the research study conducted during the course of
report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.